Admissions and Cost of Hospitalisation of Phenylketonuria: Spanish Claims Database Analysis

被引:4
|
作者
Darba, Josep [1 ]
Ascanio, Meritxell [2 ]
机构
[1] Univ Barcelona, Dept Econ, Diagonal 690, Barcelona 08034, Spain
[2] BCN Hlth Econ & Outcomes Res SL, Barcelona, Spain
关键词
NEWBORN SCREENING-PROGRAMS; INVESTIGATING TIME BURDEN; OUTCOMES;
D O I
10.1007/s40261-019-00760-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundPhenylketonuria is a well-known rare disease included in the neonatal screening of many countries. Therefore, there are few published data on the admissions and costs of phenylketonuria in Spain.ObjectiveThe objective of this study was to assess the number of admissions and the economic burden of phenylketonuria in Spain.MethodsPatients with phenylketonuria were identified from a Spanish database containing data from public and private healthcare centres from 1997 to 2015. The parameters obtained were characteristics of the patients, type of admissions, readmissions, discharges, length of stay, medical service, annual number of visits, annual number of patients, visit-associated costs and patient-associated costs.ResultsFive hundred and ninety-four patients with phenylketonuria were identified: 48.32% were male with a mean (standard deviation) age of 4.50 (10.23) years. The hospital admissions were divided into emergency visits (55.94%) and scheduled visits (43.92%). The majority of patients were discharged home (98.86%). The mean (standard deviation) duration of stay was 4.04 (4.98) days. The number of admissions per year rangedbetween 13 and 88, with an average of 1.18 admissions per patient per year. Finally, the mean cost per visit increased from Euro1064.91 to Euro3709.40, and the mean cost per patient increased from Euro1818.90 to Euro4239.32 from 1999 to 2015.ConclusionsThe access to economic and social data on phenylketonuria in Spain has been updated. The number of admissions in Spain between 1997 and 2015 and healthcare costs between 1999 and 2015 were calculated. There were 24 admissions as a result of a phenylketonuria diagnosis in 2015 and the mean healthcare cost per patient was Euro4239.32. This information can help to adapt and improve each healthcare system to take into consideration rare diseases.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 50 条
  • [31] Anxiety Disorders-Cost of Illness and Treatment Patterns Analysis from a Retrospective US Claims Database
    Francois, Clement
    Despiegel, Nicolas
    Maman, Khaled
    Saragoussi, Delphine
    Auquier, Pascal
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S147 - S148
  • [32] Healthcare cost of patients presenting with peripheral artery disease (PAD): an analysis using a claims database in France
    Riviere, A. Bura
    Bouee, S.
    Laurendeau, C.
    Gourmelen, J.
    Thomas-Delecourt, F.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1130 - 1130
  • [33] The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis
    Hoover, Alex
    Reimche, Paige
    Watson, Dave
    Finch, Mike
    Gilchrist, Laura
    Tanner, Lynn
    Messinger, Yoav H.
    Turcotte, Lucie M.
    BLOOD, 2022, 140 : 7913 - 7914
  • [34] Surgical Management of Trigeminal Neuralgia: Use and Cost-Effectiveness From an Analysis of the Medicare Claims Database
    Sivakanthan, Sananthan
    Van Gompel, Jamie J.
    Alikhani, Puya
    van Loveren, Harry
    Chen, Ren
    Agazzi, Siviero
    NEUROSURGERY, 2014, 75 (03) : 220 - 225
  • [35] HEALTHCARE COST OF PATIENTS PRESENTING WITH PERIPHERAL ARTERY DISEASE (PAD): AN ANALYSIS USING A CLAIMS DATABASE IN FRANCE
    Bouee, S.
    Laurendeau, C.
    Riviere, Bura A.
    Thomas-Delecourt, F.
    VALUE IN HEALTH, 2016, 19 (07) : A644 - A645
  • [36] THE COST OF HYPOGLYCEMIC EVENTS ASSOCIATED WITH DIABETES: A RETROSPECTIVE CLAIMS DATABASE STUDY
    Pietri, G.
    Kennedy, K.
    Bouchard, J.
    Goldhammer, M.
    VALUE IN HEALTH, 2012, 15 (04) : A177 - A177
  • [37] Estimates of the excess cost burden of Ehlers-Danlos syndromes: a United States MarketScan® claims database analysis
    Schubart, Jane R.
    Schaefer, Eric W.
    Knight, Dacre R. T.
    Mills, Susan E.
    Francomano, Clair A.
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [38] Comparing Total and Disease Related Healthcare Cost of Glaucoma Patients by Disease Severity: A Retrospective Claims Database Analysis
    Yep, Tracy
    Patel, Vaishali D.
    Slejko, Julia
    Devine, Beth
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [39] Persistent Use of Dalfampridine Extended Release on Healthcare Resource Utilization and Cost in Multiple Slerosis: A Claims Database Analysis
    Krieger, Stephen
    Niyazov, Alexander
    Macaulay, Dendy
    Terasawa, Emi
    Wu, Eric
    Aupperle, Peter
    Guo, Amy
    NEUROLOGY, 2016, 86
  • [40] MEDICAL COST EVALUATION OF APIXABAN VERSUS WARFARIN IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: JAPANESE CLAIMS DATABASE ANALYSIS
    Mishina, S.
    Murata, T.
    VALUE IN HEALTH, 2017, 20 (09) : A609 - A609